科研之友
微信
新浪微博
Facebook
分享链接
摘要
On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib mesylate (Gleevec). The patent application failed to meet the requirements for patentability under Indian law. The global public health community followed the case closely. Its outcome could affect the Indian generics industry - an important supplier of low cost medicines to the developing world.
- 出版日期2013-8
